UBS AM
KNTE

UBS AM’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

UBS AM’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-12,130
Closed -$137K – 2797
2022
Q1 		$137K Buy
+12,130
New +$134K ﹤0.01% 2715

Other funds holding KNTE

FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

UBS AM's KNTE Position: Q2 2022 in Review

UBS AM sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2022, closing a stake of 12,130 shares — an estimated $137K sold.

UBS AM first reported a position in KNTE in Q1 2022 and held it in 1 quarter. The position peaked at $137K in Q1 2022. 73 funds tracked by Wall St. Rank hold KNTE as of Q2 2022.

  • UBS AM reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • UBS AM sold 12,130 Kinnate Biopharma Inc. Common Stock shares in Q2 2022, an estimated $137K.
  • UBS AM first reported a position in Kinnate Biopharma Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • UBS AM's Kinnate Biopharma Inc. Common Stock position peaked at $137K in Q1 2022.
  • 73 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2022.

Based on UBS AM's 13F filing for Q2 2022, filed 12 Aug 2022.